PDF(Pubmed)
Abstract：
The chemokine 20 (CCL20) is a member of the CC chemokine family and plays a role in tumor immunity and autoimmune disease. This work investigated the value of CCL20 as a serum diagnostic marker for primary hepatocellular carcinoma (HCC). Based on the data of hepatocellular carcinoma patients in the TCGA database, the up-regulated genes encoding secretory proteins were analyzed in each pathological stage, and the candidate marker CCL20 gene was selected. Serum concentrations of CCL20 in patients with primary HCC, benign liver disease, and healthy subjects were analyzed by enzyme-linked immunosorbent assay (ELISA). The ROC curve evaluated the efficacy of CCL20 alone or in combination with AFP in the diagnosis of HCC. It was found the expression of CCL20 in HCC patients was significantly higher than that in the benign liver disease group and healthy controls (P < 0.05); The AUC of ROC curve to distinguish HCC patients from healthy controls was 0.859, the sensitivity was 73.42%, and the specificity was 86.84%. After combination with AFP, the AUC increased to 0.968, the sensitivity was 88.16%, and the specificity was 97.37%. Although CCL20 was increased in the serum of patients with benign liver diseases, combined with AFP, the AUC to distinguish HCC patients from non-HCC cohorts (benign liver disease group and healthy control group) was 0.902, with a sensitivity of 91.67% and a specificity of 75.26%. Collectively, serum CCL20 is closely related to the occurrence of HCC, and detection of serum CCL20 can assist AFP in improving the diagnostic sensitivity of HCC.
摘要：
趋化因子20(CCL20)是CC趋化因子家族的成员,在肿瘤免疫和自身免疫性疾病中起着重要作用。这项工作研究了CCL20作为原发性肝细胞癌（HCC）的血清诊断标志物的价值。基于TCGA数据库中肝细胞癌患者的数据，在每个病理阶段分析编码分泌蛋白的上调基因，选择候选标记CCL20基因。原发性肝癌患者血清CCL20的浓度，良性肝病,和健康受试者通过酶联免疫吸附测定（ELISA）进行分析。ROC曲线评价CCL20单独或联合AFP诊断HCC的疗效。发现CCL20在HCC患者中的表达明显高于良性肝病组和健康对照组（P<0.05）；ROC曲线区分HCC患者与健康对照组的AUC为0.859，敏感性为73.42％，特异性为86.84%。与AFP结合后，AUC增加到0.968，灵敏度为88.16%，特异性为97.37%。虽然CCL20在良性肝病患者血清中升高，再加上法新社,区分HCC患者与非HCC队列(良性肝病组和健康对照组)的AUC为0.902,敏感性为91.67%,特异性为75.26%.总的来说，血清CCL20与肝癌的发生密切相关,血清CCL20检测可辅助AFP提高HCC诊断的敏感性。
